Navigation Links
Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
Date:12/4/2008

DURHAM, N.C., Dec. 4 /PRNewswire/ -- Parion Sciences, Inc. today announced that its partner, Gilead Sciences (Nasdaq: GILD), has initiated a Phase I clinical trial of GS9411 in healthy volunteers to evaluate the safety and tolerability of the investigational compound. GS9411 is designed to increase airway hydration for the treatment of pulmonary disease. Previously known as P-680, GS9411 is an epithelial sodium channel (ENaC) blocker discovered by Parion, a privately held pharmaceutical company focused on treating diseases that result from the failure of the body's mucosal defenses.

The initiation of the Phase I trial triggers a $5 million milestone payment to Parion, according to an exclusive licensing and co-development agreement signed in August 2007 granting Gilead worldwide commercialization rights to GS9411 for the treatment of pulmonary diseases, including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and non-CF bronchiectasis. Parion and Gilead jointly performed the IND-enabling studies for GS9411, and Gilead will assume primary development responsibilities going forward. The two companies are also collaborating on a research program to identify other promising ENaC blocker-based drug candidates utilizing Parion's proprietary ENaC-based chemistry platform.

"This is an important milestone in our program to develop ENaC inhibitors to treat a range of diseases through restoring and maintaining the hydration of mucosal surfaces," said Paul Boucher, Sr. Director, Finance and Business at Parion. "Our partnership with Gilead has enabled us to accelerate development of GS9411 and successfully meet the goals and timelines for this project. We look forward to discovering the potential of this compound to provide a new treatment option for patients suffering from cystic fibrosis, COPD and other s
'/>"/>

SOURCE Parion Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Parion Sciences and Kainos Medicines Sign Clinical Development Agreement for Novel Dry Mouth Treatment
2. CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East
3. Advanced Life Sciences Announces Cethromycin NDA Accepted for Filing by FDA for the Treatment of Community Acquired Pneumonia
4. DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product
5. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
6. Frost & Sullivan Recognizes Martek Biosciences for Unique and Customer-Focused Strategies With Customer Value Enhancement Award
7. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
8. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
9. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
10. Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
11. Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... plan to release financial results for the first quarter ... after market close in the US.  ... a.m. ET on Friday, August 29, 2014 to discuss ... the Company,s recent developments, followed by a question and ...
(Date:8/21/2014)... Ontotext S4 , The Self ... . Now the same enterprise hardened text mining, ... unstructured data is available to start-ups and mid-size businesses ... Organizations that do not have resources to evaluate and ... S4 since there is no need for on premise ...
(Date:8/21/2014)... 2014 On Wednesday of last week RENU ... Redox Signaling molecules, became available for purchase in Australia and ... way that RENU 28 works is, if you think about ... the rate of cellular renewal within your body. If you ... that rate of cellular renewal. What RENU 28 does is ...
(Date:8/20/2014)... it that American Indians largely were wiped out by ... tuberculosis brought to the New World by European explorers., ... people lived in the Americas shortly before Europeans arrived, ... European diseases., But new research led by anthropological geneticists ... of the University of Tubingen in Germany indicates the ...
Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3
... /PRNewswire-Asia-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin ... pharmaceutical company with its principal operations in ... it engaged KPMG Huazhen,("KPMG"), a member firm ... firms,affiliated with KPMG International, to assist the ...
... & Company, LLC, a,Boston-based life science investment bank, ... joined the firm as senior advisor. In ... on internal and client-related activities including,merger & acquisition ... focus on biopharmaceutical transactions. "We are delighted ...
... PTNEW YORK, Jan. 13 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... Weiss, the Company,s Chairman and Chief Executive Officer, is ... Healthcare Conference being held in San Francisco.Mr. Weiss, presentation ... 1:00pm PT and will be accessible from the Investor ...
Cached Biology Technology:Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program 2Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program 3Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference 2
(Date:8/21/2014)... recently published in the journal Carcinogenesis by ... role for the protein adenomatous polyposis coli (APC) in ... deaths in the U.S. , Lead author Kristi Neufeld, ... co-leader of the Cancer Biology program at the KU ... career trying to understand the various activities of APC, ...
(Date:8/21/2014)... North Carolina State University have developed a novel and ... has applications for creating new materials as well as ... new technique allows us to model much larger and ... more quickly," says Nan Li, lead author of a ... NC State,s Department of Materials Science and Engineering. "This ...
(Date:8/20/2014)... Researchers at Huntsman Cancer Institute (HCI) at the University ... the gene that encodes BCR-ABL, the unregulated enzyme driving ... the American Cancer Society, nearly 6,000 new cases of ... in use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL ... not cure CML but control it in a way ...
Breaking Biology News(10 mins):Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Researchers develop models to study polyelectrolytes, including DNA and RNA 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... Infectious diseases can spread very rapidly, so quickly ... However, current testing for such diseases can take hours ... Jayne Wu, associate professor of computer science and electrical ... Eda, associate professor of Forestry, Wildlife and Fisheries at ...
... Health, science and medical reporters are invited to register ... Scientific Meeting March 24 at Moscone Center (North), San ... to focus on the results of care-changing investigations that ... options, advance patient care and improve quality of life. ...
... The following highlights summarize research papers that have been recently ... Journal of Geophysical Research-Earth Surface ( JGR-F ), ... Journal of Geophysical Research-Solid Earth ( JGR-B ), and ... In this release: , 1. Effect of ...
Cached Biology News:University of Tennessee researchers invent device to rapidly detect infectious disease 2Media alert: Press registration open for 2012 SIR Annual Scientific Meeting 2AGU Journal highlights - Feb. 29 2012 2AGU Journal highlights - Feb. 29 2012 3AGU Journal highlights - Feb. 29 2012 4AGU Journal highlights - Feb. 29 2012 5AGU Journal highlights - Feb. 29 2012 6AGU Journal highlights - Feb. 29 2012 7AGU Journal highlights - Feb. 29 2012 8AGU Journal highlights - Feb. 29 2012 9
... of Agilent analytical solutions is the 6890N ... (LAN) allows you to share business and ... decision making. Just as its 6890 GC ... and performance needed for research and method ...
... The 6820 GC system combines world-class ... Chemical QA/QC software, Agilents world-renowned support and ... consumables and supplies--a combination that lets you ... decisions based on dependable data. The Agilent ...
... Plus is a small and sensitive ... for both LC and IC. It features ... Pressure Ionization (API) source for outstanding sensitivity ... compatible with existing LC and IC methods, ...
... The CHEMICON® CaspaTag™ Caspase-9 Pan-Caspase In ... assay for detection of active caspases in ... research use only. Not for use in ... Situ Caspase Detection Kits use a novel ...
Biology Products: